

Introduction to Endocrinology. Diseases of the pituitary and the hypothalamus

Dr. Peter Igaz PhD DSc

**Department of Internal Medicine
and Oncology**

Department of Endocrinology

Faculty of Medicine

Semmelweis University



Fields of Endocrinology

- **Pituitary (Hypothalamus)**
- **Thyroid**
- **Parathyroid**
- **Adrenal**
- **Gonads**
- **Diabetes mellitus**
- **Multiple endocrine Neoplasia**

Causes of hypothalamic dysfunction

- **Tumors (astrocytoma, glioma, germinoma, craniopharyngeoma, big pituitary tumors, lymphoma)**
- **Bleedings**
- **Developmental abnormalities (arachnoid cysts, holoprosencephaly)**
- **Granulomatous inflammation (histiocytosis X, sarcoidosis, TBC)**
- **Inflammation (Encephalitis, Meningitis)**
- **Trauma**
- **Irradiation**
- **Inherited diseases**

Diseases of the Hypothalamus

- **Lack of trophic hormones (CRH, TRH, GnRH, GHRH) – Growth delay, Hypopituitarism, Disorders of sexual development (isolated GnRH deficiency – Kallmann-syndrome)**
- **Deficiency of posterior pituitary hormones – diabetes insipidus**
- **Non-endocrine consequences of hypothalamic disorders:**
 - **Appetite problems (Anorexia, Hyperphagy, Obesity)**
 - **Disorders of liquid homeostasis (Adipsia, Polydipsia)**
 - **Disorders of thermal regulation (Hyperthermia, Hypothermia)**
 - **Somnolence, Coma**
 - **Mood problems**

Diseases of the pituitary

- Adenomas (Micro-, Macro-, Incidentaloma)
- Anterior pituitary
 - Hormone overproduction (60-70%)
 - Prolactin
 - GH
 - ACTH
 - TSH (very rare)
 - Hormonally inactive pituitary tumors (including gonadotropin-secreting) (30-35%)

Hypopituitarism

- Posterior pituitary
 - Diabetes insipidus
 - SIADH

Micro- and Macroadenoma

- **Limit: 10 mm**
- **Consequences:**
 - **Hormone overproduction**
 - **Mass Effects**
 - **Visual field disturbance**
 - **Hormone deficiencies (1. GH, 2. LH/FSH, 3. TSH, 4. ACTH)**
 - **Increased prolactin (Stalk lesion)**
 - **Intracranial hypertension**
 - **Neurological complications**
- **Mostly benign, pituitary carcinoma is extremely rare, only in case of metastases (intracerebral, craniospinal)**

Epidemiology of pituitary adenomas

Pituitary adenomas are the most frequent intracranial tumors – Prevalence: 77/100.000

- **1. Prolactinoma**
- **2. Hormonally inactive (including Gonadotropin secretion without clinical consequences)**
- **3. GH, much rarer**
- **4. PRL + GH**
- **5. Cushing-disease**
- **6. TSH (Inzidence: 1-2/10 Million/Y)**

Investigating pituitary adenomas

- **Hormonal examinations - Screening**
 - Prolactin
 - Cortisol, ACTH
 - TSH, fT4
 - IGF-1
 - LH, FSH, Sexual steroids
- **Imaging (MRI)**
- **Ophthalmological examination**

Treatment of pituitary adenomas

- **Surgery – Macroadenomas, Visual sight defects, neurological complications, liquorrhoea, hormone overproduction (except prolactinomas)**
- **Medicamentous treatment (Prolactinoma, Acromegaly)**
- **Irradiation therapy (gamma-knife)**

Prolactinoma

- **The most common form of pituitary adenoma**
- **Microprolactinoma vs. macroprolaktinoma (Limit 10 mm)**
- **Prevalence 44/100.000**
- **Typical symptoms in women, often without symptoms in men**

Symptoms of prolactinoma

Women

- Galaktorrhoea
- Amenorrhoea/
Raromenorrhoea
- Osteoporosis
- **Mass effects in both**
- Visual field defects
- Hormone deficiency
- Neurological complications

Men

- Loss of libido
- Impotence
- Osteoporosis

Normal Prolactin levels

- Normal range: 5-20 ng/ml
- Prolactin results in prolactinoma are usually >200 ng/ml.
- In macroprolaktinomas PRL is usually >1000 ng/ml.
- Hook-Effect – in case of very high PRL, lab measurement can be false negative
- **Macroprolactin** – Polymers of prolactin – non-functional, false positive results – PEG-Reaction to exclude it

Hyperprolactinemia due to other causes

- **Drugs**
- **Pituitary stalk lesion (Trauma, Surgery, Big tumors (Macroadenoma), infiltrative lesions /e.g. sarcoidosis/)**
- **estrogen**
- **hypothyroidism**
- **Chest wall trauma**
- **Chronic renal insufficiency**

Drug causes of hyperprolactinemia

- **Dopamin-antagonist drugs (D2-Receptor Antagonists)**
- **Antipsychotic Drugs – Risperidone**
- **Antidepressants**
- **Antiemetic drugs – e.g. Metoclopramide**
- **Antihypertensive Drugs (Verapamil, Reserpine, Methyldopa)**

Macroprolaktinoma



Therapy of Prolactinoma

- **Drug Therapy – Dopamin Agonists**
 - Bromocriptin – Ergot-Derivative
 - Quinagolid
 - **Cabergolin - Ergot-Derivative**

**Surgery – threatening visual field loss,
neurological consequences, ineffective drug
treatment, lack of compliance**

Irradiation therapy



A case

- 42 year old man, complains of libido loss
- No urological cause, but testosterone level very low
- Prolaktin level 1472 ng/ml (norm. <10)
- Macroprolaktin: 247 ng/ml
- Sella MRI - Macroadenoma
- No chiasma lesion, Bromocriptin started



Before Bromocriptin

4 Years after Bromocriptin

Frontalis



Sagittalis



Akromegaly and Gigantism

Rare disease

Prevalence: 30-70/Million

Robert Wadlow
The tallest man of the world
2.72 m




Wikipedia



Anna Swan
2.27 m
With her parents

Wikipedia



Giant Gonzalez
2.29 M

Wikipedia

Maurice Tillet and Shrek



Wikipedia

Symptoms of acromegaly

- Growth of the „Acras“: Hands (Sausage fingers), feet, nose, tongue (makroglossia), ears, lips, carpal tunnel syndrome
- **Glove size? Shoe size?**
- Visceromegaly (Cardiomegaly) – Hypertension, Heart insufficiency, **Sleep apnea**
- Increased tumor prevalence – Colon polyposis, Colorectal Cc.
- Sweating
- Diabetes mellitus
- Endocrine disorders (Raromenorrhoea, Impotence)

Death causes in acromegaly

- **Cardiovascular (Heart insufficiency)**
60%
- **Respiratory (25 %)**
- **Cancer (15%)**

Laboratory diagnosis of Acromegaly

- **Screening – Serum IGF-1**
- **Confirmation - OGTT (Oral glucose tolerance test) – 75 g Glucose per os, Blood taking 0', 30', 60', 90', 120', 180'**
- **Normally GH goes below 1 ng/ml, in case of acromegaly it does not go below 2 ng/ml, often a paradoxical increase of GH is observed**

Treatment of acromegaly

- **1. Surgery**
 - Success rate for microadenomas: 70-90%
 - Success rate for macroadenomas: 50-70%
- **2. Drug Therapy**
 - Somatostatin Analogues (Octreotide, Lanreotide, Pasireotide)
 - GH-Receptor Antagonist, Pegvisomant (Somavert)
 - Dopamine Agonists (Cabergolin)
- **3. Irradiation**

A case of acromegaly

- The new GP of a 41 Y old man noticed the typical face changes. He had a history of insulin-treated diabetes mellitus for 3 years.
- IGF-1 942 (strongly increased), paradoxal increase during OGTT
- Sella MRI showed a pituitary macroadenoma
- Operation via parasseptal-transsphenoidal route
- Postop. OGTT: no suppression – Op. unsuccessful

Case of acromegaly 2.

- **Somatostatin Analogue, Octreotide LAR started, IGF-1 reduced, but not normalized**
- **MRI control shows a residual tumor (recurrence), reoperation**
- **Postop. OGTT: again no suppression**
- **Octreotide LAR than, Lanreotide, IGF-1 not normalized**
- **Pasireotid LAR started, then IGF-1 became normal. Insulin doses had to be increased.**

- **Primary insufficiency**

- Disease of the peripheral hormone producing organ (thyroid, adrenal cortex, gonads)
- peripheral hormone low, pituitary hormone increased

- **Secondary insufficiency**

- Lack of the pituitary front lobe hormones
- Peripheral hormone low, pituitary hormone low

- **Tertiary insufficiency**

- Lack of hypothalamic trophormones, all hormone levels are low

Hypopituitarism

Pituitary anterior lobe insufficiency

- **Loss of one or more anterior lobe hormones**
- **Prevalence 46/100.000, Incidence: 4/100.000/Y**
- **Order of the loss of anterior lobe hormones:**
 - 1. GH
 - 2. LH/FSH
 - 3. TSH
 - 4. ACTH

Causes of Hypopituitarism

- **Neoplastic – pituitary/sellar or hypothalamic tumors**
- **Traumatic – Operation, Trauma, Irradiation**
- **Congenital – e.g. Prader-Willi sy, Laurence-Moon-Biedl sy, Kallmann sy**
- **Inflammatory – autoimmune hypophysitis, TBC, Syphilis, Meningoencephalitis**
- **Infiltrative - Sarcoidosis, Histiocytosis X, Hämochromatosis**
- **Vascular – postpartal necrosis (Sheehan-syndrome), Carotis-aneurysm, cavernous sinus thrombosis, stroke**
- **Drug-induced (long steroid therapy)**

Sheehan-Syndrome

- **Pituitary infarction in the peripartal period**
- **Milder Case – Mangel von Muttermilch, Prolaktinverlust, dann weitere Symptome des Hypopituitarismus, Verlust von Sexualbehaarung, Amenorrhö bleibt nach der Geburt**
- **Schwieriger Fall – Anorexie, Gewichtsverlust, Lethargie**

Symptoms

- Weight loss, fatigue, weakness, fine wrinkles on the face, hypotension
- Secondary hypogonadism – loss of libido, secondary amenorrhea, impotence
- Secondary hypothyroidism – cold intolerance, bradycardia, obstipation, hyponatremia
- Secondary adrenal insufficiency – hypotension, weakness, paleness, malaise, hyponatremia
- **No aldosterone deficiency – NO hyperkalemia**
- Prolactin deficiency – Inability to lactate (Stalk lesion leads to mildly increased prolactin)
- GH-deficiency in adults – Fatigue, muscle loss, increased fat

GH-Deficiency

- **In children**
 - Proportional dwarfism
- **In adults**
 - Change in body composition– increased fat
 - Reduced muscle amount
 - Reduced life quality
 - Dyslipidemia
 - Cardiovascular risk factors





Hormonal Diagnosis

- LH, FSH low – Testosterone, estradiol (E2) low - secondary hypogonadism

(In contrast, in primary hypogonadism, LH, FSH are high)

- IGF-1 low – GH-deficiency
- TSH low, fT4 low (in primary hypothyroidism, TSH is high)
- ACTH low, cortisol low (in M. Addison, ACTH is high) – if cortisol is >20 ug/dl (540 nmol/l) in the morning, adrenal insufficiency is excluded
- Synacthen-test – 250 ug Tetracosactid, 60' later Kortizol > 20 ug/dl (540 nmol/l) – *the adrenal cortex atrophies in ACTH-deficiency*

Dynamic Tests in the diagnosis of hypothalamus-pituitary diseases

- **TRH-Stimulation**
- **LHRH-Stimulation**
- **Insulin-Hypoglycemia**

Insulin-Hypoglycemia Test

- Hypoglycemia provokes ACTH and GH
- 0.1-0.15 E/Kg rapid acting insulin i.v.
- Blood taken every 15 Min. after insulin and during hypoglycemia (blood sugar <2.2 mmol/l)
- GH deficiency:
 - GH < 3 ng/ml in adults
 - GH < 7 ng/ml in children

Therapy 1.

- **Glucocorticoid substitution**

- Hydrocortison – 15-20 mg/D – highest dose in the morning
- Prednisolon 5 mg/D
- Strong increase in acute cases (e.g. 3x100 mg Hydrocortison/D intravenously in shock, surgery)

- **L-Thyroxine**

- 1.6-1.8 $\mu\text{g}/\text{kg}/\text{D}$ – in general 100-150 $\mu\text{g}/\text{D}$ - **monitoring fT4**

ALWAYS GLUCOCORTICIDS FIRST, THEN L-THYROXINE

Therapy 2.

- **Substitution with sex hormones**
 - 1. **Development and maintenance of secondary sex characteristics**
 - Testosterone – Injection, Transdermal
 - Estrogen substitution
 - 2. **Development of fertility**
 - LH/FSH Substitution, β -HCG
- **GH-Substitution**
 - **Daily GH administration, approx. 1 IU/D (monitor with IGF-1)**

DIABETES INSIPIDUS

Main forms of Diabetes insipidus

- **Central Diabetes insipidus.**
- **Nephrogenic diabetes insipidus.**
- **Transient Diabetes insipidus during pregnancy (due to increased ADH metabolism)**
- **„Primary Polydipsia” – mostly in psychiatric diseases or bad habit, the most important differential diagnostic issue**

Main causes of central Diabetes insipidus

- **Not frequent, incidence: 4/100.000 Person/Y**
- **Main causes:**
 - **Trauma**
 - **Neurosurgery (for a pituitary tumor)**
 - **Tumors of the hypothalamus and pituitary**
 - **Rare inflammatory diseases (Histiocytosis X, Sarcoidosis)**
 - **Intracranial bleeding, Sheehan Syndrom**
 - **Very rare congenital forms**

Main symptoms and diagnosis of Diabetes insipidus

- Polyuria, variable, can reach 18-20 Liter per day in the most severe forms.
- Polydipsia.
- Low urine density(1001-1005 g/cm³) and Osmolality (<200 mosmol/kg).
- Thirst probe: the patient cannot concentrate the urine – danger of exsiccosis
- Oral Water and Salt administration (20 ml/kg water and 0.9 % NaCl for 2 days): in healthy people, the diuresis after NaCl is lower than after water.
- Differential diagnosis between central and nephrogenic DI: administration of desmopressin leads to reduction of urine production in central DI

Treatment of central DI

- ADH is not stable enough for clinical use
- ADH-analogue Desmopressin, DDAVP mostly as nasal spray, also available as tablets
- Daily dose: 1-2x 1 Spray, or 3x100-200 μg in tablets.

Nephrogenic DI

- **Problem of the renal effect of ADH**
- **Two main forms:**
 - Rare congenital forms (VP2 or AQP2 mutations)
 - Acquired forms (chronic renal diseases, metabolic disorders /hypercalcemia, hypokalemia, gout/, osmotic diuretics /mannitol/, drugs /lithium, demeclocyclin, vincristin/)
- **Treatment:**
 - NSAID (Indomethacin, Ibuprofen, Aspirin) reduces the polyuria, increases osmolality
 - mild volume depletion, thiazides in combination with NSAID. K-sparing diuretics (amilorid) + thiazides is also effective.